Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gufic BiosciencesBOM:509079 -0.36%75 PEG Ratio is 8.42 as of Jul. 15, 2026, which is 543% above its 10-year median of 1.31. GuruFocus rates BOM:509079 with a GF Score™ of 75/100 and a GF Value™ of ₹409.13 (Fairly Valued). The stock has 7 warning signs investors should review. Among 348 Drug Manufacturers companies, Gufic Biosciences ranks worse than 87.07% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Gufic Biosciences's PEG Ratio or its related term are showing as below:
BOM:509079'
s PEG Ratio Range Over the Past 10 Years
Min: 0.37 Med: 1.31 Max: 22.27
Current: 8.42
During the past 13 years, Gufic Biosciences's highest PEG Ratio was 22.27. The lowest was 0.37. And the median was 1.31.
BOM:509079's PEG Ratio is ranked worse than 87.07% of 348
companies
in the Drug Manufacturers industry
Industry Median: 1.725
vs BOM:509079: 8.42
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Gufic Biosciences (BOM:509079) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Gufic Biosciences PEG Ratio Related Terms
Gufic Biosciences PEG Ratio Historical Data
* Premium members only.
The historical data trend for Gufic Biosciences's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gufic Biosciences PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Gufic Biosciences's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Gufic Biosciences (BOM:509079) has a PEG Ratio of 8.42 as of Jul. 15, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Gufic Biosciences and its competitors. This is 543% above median its historical median of 1.31. Over the past decade, Gufic Biosciences' PEG Ratio has ranged from 0.37 to 22.27. According to the industry distribution chart, Gufic Biosciences ranks #303 out of 348 companies in the Drug Manufacturers industry, placing it in the top 87.1%.
Is Gufic Biosciences' PEG Ratio too high?
Gufic Biosciences' current PEG Ratio of 8.42 is 543% above median its 10-year median of 1.31. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 22.27. The Drug Manufacturers industry median PEG Ratio is 1.73. Gufic Biosciences' value of 8.42 is 388.1% above this industry median. Based on the distribution chart, Gufic Biosciences ranks #303 out of 348 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gufic Biosciences has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gufic Biosciences' PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gufic Biosciences ranks #303 out of 348 companies for PEG Ratio. This places Gufic Biosciences in the lower half of its industry. The industry median PEG Ratio is 1.73. Gufic Biosciences' value of 8.42 is 388.1% above this benchmark. Historically, Gufic Biosciences' own PEG Ratio has ranged from 0.37 to 22.27 over the past decade. While the company's 10-year median is 1.31 vs. the industry median of 1.73, Gufic Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.73, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gufic Biosciences's current PEG Ratio of 8.42 is 388.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Gufic Biosciences and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gufic Biosciences's current PEG Ratio is 8.42, which is 543% above median its own 10-year median of 1.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gufic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Gufic Biosciences (BOM:509079) is currently considered Fairly Valued. The stock's GF Value™ is ₹409.13, compared to a current price of ₹398.65 — trading 2.6% below its estimated fair value. The current PEG Ratio is 8.42, which is 543% above median its 10-year median of 1.31 and 388.1% above the Drug Manufacturers industry median of 1.73. Gufic Biosciences' overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Gufic Biosciences (BOM:509079), the current PEG Ratio is 8.42 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gufic Biosciences (BOM:509079) Overvalued in 2026?
Based on GuruFocus' analysis, Gufic Biosciences stock appears to be undervalued.
The current stock price of ₹398.65 is trading 2.6% below its estimated GF Value™ of ₹409.13.
GuruFocus considers Gufic Biosciences to be Fairly Valued.
Key valuation signals for BOM:509079:
PEG Ratio: 8.42 (543% above median its 10-year median of 1.31)
GF Value™: ₹409.13 vs. price of ₹398.65 (2.6% below fair value)
Industry Position: 388.1% above the Drug Manufacturers median (#303 of 348)
No single metric tells the full story. See the BOM:509079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
75GF Score
Get the complete analysis for BOM:509079
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:509079 has been successfully added to your 
